A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.
Status:
Completed
Trial end date:
2005-09-01
Target enrollment:
Participant gender:
Summary
This study will assess the efficacy and safety of subcutaneous (sc) Mircera given as
maintenance treatment for renal anemia in chronic kidney disease patients on dialysis who
were previously receiving sc epoetin. The anticipated time on study treatment is 1-2 years
and the target sample size is 100-500 individuals.